Literature DB >> 16701965

New understanding of immunological mechanisms.

Armin Saalmüller1.   

Abstract

The understanding and importance of antigen-specific immune responses after vaccination has completely changed in recent years. In the past, the focus for monitoring a vaccine-specific immune reaction was principally on the humoral branch of the immune system. The efficacy of vaccines, as assessed by the induction of protective immunity was mainly correlated with antibodies and antibody-titers. However, this correlation often failed and other parts of the immune system had also to be considered: namely, the innate immune system and the cellular branch of the antigen-specific immune system. With regard to vaccines, the innate immune system plays its main role in the effective activation of the antigen-specific immune response, in antigen-uptake and antigen-presentation. The dendritic cells (DCs) are the most important antigen presenting cells which present processed protein antigens (peptides) through MHC-molecules: MHC-class I, for the presentation of endogenous synthesised antigen; MHC-class II for exogenous antigen. Activation of DC leads to an enhanced production of cytokines and chemokines, to an up-regulation of co-stimulatory and activation molecules and also molecules for cell-cell interactions, e.g. interactions with cells of the antigen-specific immune system. T lymphocytes are the effector cells of the cellular branch of the antigen-specific immune system. They act either as MHC-class I-restricted cytolytic T lymphocytes (CTL) or as MHC-class II-restricted T-helper cells providing support for B lymphocytes (T(H)2) and the cellular part of the antigen-specific immune system (T(H)1). In order to achieve effective vaccination, the activation of all T-cell subpopulations is of advantage, but more important is the generation of antigen-specific memory T and B lymphocytes. In addition to these 'generic' immunological factors which are essential for the design of more efficacious vaccines, our detailed knowledge about feline and canine immune reactions after vaccination, which is still poor, has to be improved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16701965     DOI: 10.1016/j.vetmic.2006.04.007

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

2.  Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity.

Authors:  Yangtai Guan; Shuo Yu; Zhao Zhao; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2007-11-19       Impact factor: 3.478

3.  Porcine SWC1 is CD52--final determination by the use of a retroviral cDNA expression library.

Authors:  Judith Leitner; Katharina Reutner; Sabine E Essler; Irene Popow; Wilhelm Gerner; Peter Steinberger; Armin Saalmüller
Journal:  Vet Immunol Immunopathol       Date:  2012-01-21       Impact factor: 2.046

Review 4.  Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization.

Authors:  Ning Wang; Minnan Chen; Ting Wang
Journal:  J Control Release       Date:  2019-05-03       Impact factor: 9.776

5.  In vivo and in vitro characterization of the immune stimulating activity of the Neisserial porin PorB.

Authors:  Andrew Platt; Heather MacLeod; Paola Massari; Xiuping Liu; Lee Wetzler
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

6.  Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus.

Authors:  T Almeras; P Schreiber; S Fournel; V Martin; C S Nicolas; C Fontaine; C Lesbros; S Gueguen
Journal:  BMC Vet Res       Date:  2017-10-10       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.